View Post

Increasingly Specific ctDNA Assays Are Set to Define the Future of Breast Oncology

In In The News by Barbara Jacoby

By:Ashling Wahner From: onclive.com Key Takeaways ctDNA testing is emerging as a key tool in breast cancer management, aiding in early detection and treatment monitoring. Ultra-sensitive assays like Signatera demonstrate high sensitivity and specificity in detecting distant relapses in breast cancer. ctDNA testing could enable treatment de-escalation or escalation based on MRD status, potentially transforming clinical practice. Despite current challenges, …